Palazestrant
Palazestrant is an investigational new drug which is being evaluated for the treatment of estrogen receptor-positive breast cancer, with a dual mechanism of action as both a complete estrogen [receptor antagonist] and a selective [estrogen receptor degrader]. This orally bioavailable small molecule has demonstrated potent activity against both wild-type and mutant forms of the estrogen receptor.